Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies

Share this

Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies


  • The US FDA grants approval to Roche’s Xolair (omalizumab) for reducing allergic reactions like anaphylaxis caused by accidental exposure to one or more foods in IgE-mediated food allergic adult and pediatric patients (1yr. & above)
  • The approval was supported by results of the P-III (OUtMATCH) trial assessing Xolair vs PBO for reducing allergy in patients (1yr. to 55yrs.) due to peanuts and at least two other food allergens
  • The results demonstrated that treatment with Xolair after 16-20wks. showed tolerance of 600mg peanut protein (68% vs 5%), 1,000mg protein from milk (66% vs 11%), egg (67% vs 0%) or cashew (42% vs 3%) without moderate to severe allergic symptoms was seen in high no. of patients

Ref: Roche | Image: Roche

Related News:- Alvotech Entered into an Exclusive License Agreement with Kashiv BioSciences to Develop and Commercialize AVT23, a Proposed Biosimilar to Xolair (omalizumab)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions